• Introduction to Cancer Therapy
• 46 min
  1. Development of a cancer drug

  • Prof. Martin Edelman
• Use of Novel "Targeted" Agents in Combination with Classical Cytotoxic Chemotherapy
• 35 min
  2. Small molecule inhibitors of receptor tyrosine kinases

  • Dr. Daniela Krause
• Innovative Strategies of Clinical Drug Development
• 46 min
  3. Phase II trials

  • Dr. Patricia Tang
• 33 min
  4. Surrogate endpoints of efficacy

  • Prof. Maurie Markman
• Biomarkers in Oncology: Rationale Development and Current Use
• 27 min
  5. Biomarkers in oncology: overview

  • Prof. Joe Duffy
• 55 min
  6. Genetic polymorphism of thiopurine methyltransferase and thiopurine therapy: from molecular genetics to clinical medicine

  • Dr. William Evans
• Archived Lectures *These may not cover the latest advances in the field
• 42 min
  7. Emerging trends in phase II trial design

  • Dr. Patricia Tang
• 36 min
  8. EGFR inhibitors in NSCLC and the role of biomarkers for selection of patients

  • Prof. Fred Hirsch
• 36 min
  9. Therapy in cancer 2008: quo vadis?

  • Dr. Jeffrey Clark
• 34 min
  10. Changing paradigms in anticancer drug development: inhibiting angiogenesis in colorectal cancer

  • Prof. David Kerr
• 32 min
  11. Phase III trials

  • Prof. Martin Edelman
• 43 min
  12. Germline pharmacogenomics as a tool to individualize therapy in breast cancer

  • Dr. David Flockhart
• 33 min
  13. Gene profiling in breast cancer

  • Dr. Enrique Espinosa
• 31 min
  14. UGT1A1 polymorphisms and irinotecan toxicity in colorectal cancer patients

  • Prof. Tae Won Kim
• 28 min
  15. Principles of cancer treatment: surgery, radiotherapy, chemotherapy, immunotherapy

  • Dr. Theodore Yaeger
• 25 min
  16. Understanding cancer trends

  • Prof. Michael Thun
• 54 min
  17. Bevacizumab: the first FDA-approved angiogenesis inhibitor in the treatment of non-small cell lung cancer

  • Dr. Tracey Evans
• 40 min
  18. Phase I study design for non-cytotoxic agents

  • Dr. Wendy Parulekar
• 36 min
  19. Early detection of lung cancer

  • Prof. Stephen Lam
• 60 min
  20. Cytotoxic chemotherapy

  • Dr. Michael Sawyer

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Irinotecan (CPT-11, camptosar)
3. Treatment of metastatic CRC
4. Safety of irinotecan (1)
5. Safety of irinotecan (2)
6. Illustration of metabolic pathway of irinotecan
7. Glucuronidation of SN-38 vs. toxicity
8. Schematic illustration of UGT1A
9. Candidate polymorphism: UGT1A1*28, (TA)7
10. UGT1A1*28 genotype-phenotype association (1)
11. UGT1A1*28 genotype-phenotype association (2)
12. Revised irinotecan package insert (Mar 2005)
13. Invader: UGT1A1molecular assay (Aug 2005)
14. Role of UGT1A1*28 in metastatic CRC
15. Unanswered questions
16. UGT1A1*28 frequency in 3 different ethnic groups
17. Another candidate polymorphism: UGT1A1*7
18. Frequency of UGT1A1*6 in Asians
19. UGT1A1*6 genotype-phenotype association
20. Efficacy in UGT1A1*28-genotyped patients
21. Irinotecan dose and hematologic toxicity
22. Individualization of chemotherapy
23. Genotype-based dosing of irinotecan (1)
24. Genotype-based dosing of irinotecan (2)
25. Role of other UGT1A
26. Metabolic pathway of irinotecan: transporters
27. Limitation of previous studies
28. Conclusions

Topics Covered

• Irinotecan activity and safety
• Metabolism of Irinotecan
• Structure of UGT1A
• Role of UGT1A1*28 on irinotecan pharmacogenetics
• Role of UGT1A1*6 in Asians
• Genotype-based dosing of irinotecan
• Other candidates: UGT1A enzyme or transporter

Links

Series:

• Cancer Therapy

Categories:

• Cancer
• Clinical Practice
• Genetics & Epigenetics

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on January 6, 2009
• Archived on February 25, 2021

Financial Disclosures

• Prof. Tae Won Kim has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.